This is consistent with data from an in vivo bone tumor growth model showing that enzalutamide treatment is more effective in tumours expressing ERG [59], as well as with an earlier clinical study demonstrating that patients having PSA decline during abiraterone treatment were significantly more likely to have ERG rearrangements [60]. The gene discussed is ERG; the disease is bone neoplasm.